The stimulator helps treat muscle atrophy through electrotherapy treatments during rehabilitation. The treatments also manage pain and reduce swelling. The Empi Phoenix received FDA 510(k) clearance in May.
Michael Levine, MD, was the lead researcher on the device’s clinical trial for effectiveness. His year-long study was released in Orthopedics Today, and it showed patients who receive neuromuscular electrical stimulation have similar outcomes as patients with standard post-operative physician therapy.
More Articles on Devices:
AxoGen Interest Costs Stifle Q2 Revenue Gains, Result in $6.9M Net Loss
Study: Spinal Elements’ Ti-Bond PEEK Coating 5 Times Stronger Than Traditional Devices
Zimmer Begins Distribution of APEX Spine System
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
